Susac syndrome treated with subcutaneous immunoglobulin

Area of Science:

• Neurology
• Immunology
• Ophthalmology

Background:

• Susac syndrome is a rare autoimmune endotheliopathy affecting young women, characterized by encephalopathy, retinal artery occlusions, and hearing loss.
• Current treatment relies on limited data from case reports and small series, involving glucocorticoids, immunosuppressants, and intravenous immunoglobulin.
• Antibodies against the endothelium suggest an autoimmune basis targeting the brain, inner ear, and retina.

Observation:

• Two young women with Susac syndrome experienced recurrent episodes of encephalopathy, branch retinal artery occlusions, and hearing loss.
• Initial treatment involved various immunosuppressive drugs, glucocorticoids, and intravenous immunoglobulin.
• Treatment was successfully transitioned to subcutaneous immunoglobulin, leading to no further relapses in both patients.

Findings:

• Subcutaneous immunoglobulin administration is easily learned and allows for greater flexibility in daily life.
• This therapy potentially reduces the reliance on other immunosuppressive agents.
• Subcutaneous immunoglobulin appears effective in preventing further relapses of Susac syndrome.

Implications:

• Subcutaneous immunoglobulin offers a practical and potentially more effective treatment option for Susac syndrome.
• Reduced in-hospital costs and improved patient quality of life are significant benefits.
• Further research into subcutaneous immunoglobulin for Susac syndrome may refine treatment protocols for this rare condition.